CTAS vs MRNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Jul 30, 2026
CTAS
MRNA
Investment Advisor Scores
MRNA
AI Analyst Insights
Detailed Metrics Comparison
| Metric | CTAS | MRNA | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 38.7597 | 23.0415 | MRNA |
| PEG Ratio | 3.3531 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 8.9% | 260.2% | MRNA |
| Earnings Growth | 15.6% | -85.1% | CTAS |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 46.9/100 | 52.3/100 | MRNA |
| Profit Margin | 17.8% | -143.6% | CTAS |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
CTAS
MarkupPrice above SMA50, rising 50-day trend (7.6% over 20 days), RSI 57
MRNA
NeutralMixed signals - no dominant trend phase, RSI 49
Fundamentals Snapshot
| Metric | CTAS | MRNA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 37.4 | -11.0 |
| Trailing P/E | 41.2 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.0% |
| Gross Margin | 0.5% | -0.7% |
| Operating Margin | 0.2% | -5.6% |
| EPS | 4.91 | -7.88 |
| Dividend Yield | 0.01% | — |